Pharmaceutical manufacturer GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in the first quarter of 2021, including overcharges for blockbuster respiratory drugs Trelegy and Nucala.
The refund notice posted Feb. 2 on the U.S. Health
…
Drugmakers Lilly, Novartis, and United Therapeutics this week urged federal appeals courts in Chicago and Washington, D.C., to follow the lead of the appeals court in Philadelphia and uphold their restrictions on 340B providers’ use of contract pharmacies.
Lilly on
…
Missouri lawmakers have reintroduced legislation to prohibit drug manufactures from denying 340B covered entities access to manufacturers’ products if the covered entity uses contract pharmacies. The language is modeled on the first-of-its kind law passed in Arkansas in 2021.
Missouri
…
Oregon legislators have introduced a bill that would prohibit discriminatory practices by pharmacy benefit managers and insurance plans against 340B pharmacies, including reimbursing a 340B pharmacy less for prescription drugs compared with non-340B pharmacies.
If passed later this year, House
…
Private practice oncologists have paid for a study to model what would happened in 2023 if Medicare paid 340B hospitals for physician administered drugs based on a survey of those hospitals’ drug acquisition costs taken during the COVID pandemic’s darkest
…
Retail prescription drug spending in the U.S. shot up 7.8% to $378 billion in 2021, more than double the 3.7% spending growth rate in 2020, as the easing of the COVID-19 pandemic brought a surge in doctor visits and a
…
As we reported on deadline on Tuesday, a federal district court ruled this week that Arkansas’ novel 340B antidiscrimination law is not preempted by federal laws governing the 340B program, a decision that strikes down one of two legal arguments
…
California-based AIDS Healthcare Foundation (AHF) last week refiled its lawsuit against Delaware-based federally contracted 340B prime vendor Apexus, setting forth facts that AHF argued gives a federal district court in California jurisdiction over the case.
AHF, based in Los Angeles,
…
Lack of data makes it hard to assess the 340B program’s overall impact on drug prices charged by pharmaceutical companies and covered entities, a new study by healthcare consulting and lobbying firm Leavitt Partners concludes.
“We found compelling evidence that
…*Sign up for news summaries and alerts from 340B Report